January Schema: S T R A T I F Y. Age 1. <50 2. >50
|
|
- Kory Barker
- 5 years ago
- Views:
Transcription
1 January RTOG Protocol No: 9813 Protocol Status: ECOG Protocol No: R9813 Phase I: Opened June 16, 2000 NCCTG Protocol No: R9813 Closed January 25, 2002 SWOG Protocol No: R9813 Phase III: Opened October 15, 2002 Title: A Phase I/III Randomized Study of Radiation Therapy and Temozolomide versus Radiation Therapy and BCNU for Anaplastic Astrocytoma (IND #60,265) Patient Population: - Histologically confirmed anaplastic astrocytoma or mixed oligodendroglial/astrocytic tumors if the oligodroglial component is 25%. - No prior irradiation to the head, neck, or chemotherapy for any reason - Karnofsky performance status > 60 - Hgb > 10, absolute neutrophils > 1500, platelets > 150,000; liver function tests (AST/SGOT, alkaline phosphatase, total bilirubin < 2 x upper limit of normal); serum creatinine < 1.5 x normal. - Therapy must begin within 5 weeks after tissue diagnosis - No spinal cord tumors or spinal cord metastases - No prior invasive malignancy unless disease free > 5 years - No active infectious process - DLCO > 70% - Signed study-specific consent form prior to randomization Objective: 1. To compare overall survival. 2. To compare time to tumor progression. 3. To compare the relative toxicities of the two drug regimens. 4. To correlate molecular analyses with #1 and #2. Schema: S T R A T I F Y Age 1. <50 2. >50 KPS Surgery 1. Biopsy only 2. Resection R A N D O M I Z E Arm 1: Radiation Therapy: 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week x 6 weeks) plus Temozolomide 200 mg/m 2 daily on days 1-5 of the first week of radiotherapy. Repeat Temozolomide every 28 days for a total of 12 cycles. Arm 2: Radiation Therapy: 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week x 6 weeks) plus BCNU (80 mg/m 2 ) on days 1, 2, and 3 of the first week of radiotherapy and on days 56, 57, and 58 then every eight weeks for four cycles for a total of six cycles (maximum BCNU dose 1440 mg/m 2 ) Arm 3: (Radiation Therapy, BCNU, Temozolomide). Dropped; see section 1.3 Pilot #1, Arm 4: Pilot #2, Arm 5: Radiation Therapy: 59.4 (1.8 Gy x 33 fractions, 5 days a week x 6 weeks) plus BCNU 200 mg/m 2 on day 1 of radiotherapy and Temozolomide 150 mg/m 2 on days 1-5 of the first week of radiotherapy. Repeat every six weeks for a total of six cycles (maximum BCNU dose 1200 mg/m 2 ). (closed 3/15/01) Radiation Therapy: 59.4 (1.8 Gy x 33 fractions, 5 days a week x 6 weeks) plus BCNU 150 mg/m 2 on day 5 of radiotherapy and Temozolomide 150 mg/m 2 on days 1-5 of the first week of radiotherapy. Repeat every eight weeks for a total of six cycles. BCNU will be given on day 5 of Temozolomide in these cycles (maximum BCNU dose 900 mg/m 2 ). (closed 1/25/02)
2 January Study Chairs: Susan M. Chang, M.D. (Neuro-Oncology) Patients randomized as of: Gregory J. Cairncross, M.D. (Medical Oncology) 11/14/03 54 Mark R. Gilbert, M.D. (Medical Oncology) Jean-Paul Bahary, M.D. (Radiation Oncology) Carol A. Dolinskas, M.D. (Neuroradiology) Ken Aldape, M.D. (Neuropathology and Molecular Genetics) Peter Bushunow, M.D. (ECOG) Kurt Jaeckle, M.D. (NCCTG) Paul Brown, M.D. (NCCTG) Geoffrey R. Barger, M.D. (SWOG) Statisticians: Research Associate: Dosimetrist: Protocol Associate: Wendy Seiferheld, M.S. Minhee Won, M.A. Barbara Kaiser, R.N., C.C.R.P. Elizabeth Martin, B.S., R.T.T. Ellen Aiken, B.A. I. Summary: This study had two pilot arms in order to assess the toxicity and feasibility of combining BCNU and Temozolomide. Fifteen patients were enrolled on Pilot #1, which closed March 15, Fourteen patients were enrolled on Pilot #2, which closed January 25, Pilot arm toxicity data was presented at SNO 2002 and a manuscript reporting this data has been submitted. It was determined that the combination of RT + Temozolomide + BCNU is not feasible, thus arm 3 was dropped. The phase III component was activated October 15, 2002, and the tables in this report will address only the patients on the randomized component. Twenty-eight patients have toxicity data (Table 4). There were two grade 3 infections in RT + BCNU arm and none on RT+Temozolomide arm. One grade 4 dermatology/skin toxicity was reported in RT + BCNU arm. Only one late RT toxicity was reported (grade 2 skin within the irradiated field). The initial interim analysis of the primary endpoint is planned after the number of deaths has reached 36. II. Administrative Information: Table 2.1 Patient Accrual Estimated number of patients needed to be randomized 454 Patients randomized as of November 14, Average monthly accrual* 3.9 Average monthly accrual in the past 3 months 5.0 *The calculation is based on the date the study re-opened for randomization (October 15, 2002).
3 January Table 2.2 Randomized Accrual by Participating Institution (Arms 1 & 2) ECOG (N=2) Lankenau Hospital 1 West Virginia Univ Med Center 1 NCCTG (N=4) Cedar Rapids 1 Rochester Methodist Hospital 1 RTOG (N=40) Foundation for Cancer Res. and Edu. 4 LDS Hospital 4 Notre Dame Hospital/Univ. of Montreal 4 Partners/Dana Farber Cancer Institute 4 Univ. of Texas-MD Anderson Can. Ctr. 3 Fox Chase Cancer Center 2 Univ. of California Davis Med. Ctr. 2 University of Miami 2 University of Rochester 2 Dartmouth Hitchcock Medical Center 1 H. Lee Moffitt Cancer Center 1 SWOG (N=8) Kaiser Permante Medical Center 2 University of Utah 2 Oregon Health Sciences Center 1 Saskatchewan 1 Siouxland Regional Cancer Center 1 Johns Hopkins Hospital 1 Kansas City CCOP 1 Mayo Clinic 1 Medical College of Wisconsin 1 Metro-MN CCOP 1 Natalie Warren Bryant Can.Ctr. at St.Francis Hosp. 1 Roswell Park Cancer Institute 1 SUNY Health Science Center/Brooklyn 1 Thomas Jefferson University Hospital 1 University of Kentucky Hospital 1 West Michigan Cancer Center CCOP 1 Scott and White Clinic and Hospital 1 Univ. of Arkansas Medical Center 1 Univ. of Washington Medical Center 1 Table 2.3 Status of Cases RT + Temozolomide RT + BCNU Total Patients Entered Ineligible* 0 1 Eligible/Pending** No On-Study Form Analyzable *Arm CN Status Reason RT+BCNU 43 Ineligible Randomized 41 days after tissue diagnosis **Arm CN Status Reason RT+BCNU 67 Pending KPS in query
4 January III. Pretreatment Characteristics: Table 3 Pretreatment Characteristics RT + Temozolomide (N=16) RT + BCNU (N=15) Age <50 10 (63%) 7 (47%) 50 6 (37%) 8 (53%) Gender Male 11 (69%) 7 (47%) Female 5 (31%) 8 (53%) Race White 15 (94%) 13 (86%) Hispanic 0 1 ( 7%) African American 1 ( 6%) 1 ( 7%) KPS (44%) 4 (27%) (56%) 10 (66%) Pending 0 1 ( 7%) Surgery Biopsy 5 (31%) 5 (33%) Partial Resection 6 (38%) 6 (40%) Total Resection 5 (31%) 4 (27%) Neurologic Function No Symptoms 3 (19%) 6 (40%) Minor Symptoms 8 (50%) 9 (60%) Moderate Symptoms 5 (31%) 0
5 January IV. Toxicities: Table 4 Toxicities RT + Temozolomide (N=13) Grade RT + BCNU (N=8) Grade Allergy/immunology Auditory/Hearing Blood/Bone Marrow Cardiovascular (General) Constitutional Symptoms (Fatigue) Constitutional Symptoms (Other) Dermatology/Skin * Gastrointestinal (Constipation) Gastrointestinal (N/V) Gastrointestinal (Other) 6 0 1* Hemorrhage Hepatic Infection/Febrile Neutropenia * 0 Metabolic/Laboratory Neurology Ocular/Visual Pain (Headache) Pain (Other) Pulmonary Renal/Genitourinary Maximum Toxicity per Patient Maximum Non-Hematologic Toxicity per Patient Most Recent Days from Arm CN Toxicity Grade Description/Comment Cycle of CT Start of RT RT + Temozolomide 35 Gastrointestinal (Other) 3 Dehydration 4 85 RT + BCNU 31 Dermatology/Skin 4 Alopecia 2 77 Infection/febrile neutropenia 3 Infection w/neutropenia Infection/febrile neutropenia 3 Infection w/neutropenia 1 26
June Schema: S T R A I T I F Y. Age 1. <50 2. >50
June 2003 9813-1 RTOG Protocol No: 9813 Protocol Status: ECOG Protocol No: R9813 Opened: June 16, 2000 NCCTG Protocol No: R9813 SWOG Protocol No: R9813 Title: A Phase / Randomized Study of Radiation Therapy
More informationJune Patient Population:
June 2003 9802-1 RTOG Protocol No: 9802 Protocol Status: ECOG Protocol No: R9802 Opened: October 31, 1998 NCCT Protocol No: R9802 Closed: June 27, 2002 SWOG Protocol No: R9802 Title: A Phase II Study of
More informationJune Arm 1 = Observe R A N D O M I Z E
June 2004 9802-1 RTOG Protocol No: 98-02 Protocol Status: ECOG Protocol No: R9802 Opened: October 31, 1998 NCCT Protocol No: R9802 Closed: June 27, 2002 SWOG Protocol No: R9802 Title: A Phase II Study
More informationJanuary NCCTG Protocol No: N0628 Opened: November 27, 2007 CALGB Protocol No: ECOG Protocol No: R0617
January 2010 0617-1 RTOG Protocol No: 0617 Protocol Status: NCCTG Protocol No: N0628 Opened: November 27, 2007 CALGB Protocol No: 30609 ECOG Protocol No: R0617 Title: A Randomized Phase III Comparison
More informationNCCTG Status Report for Study N September 2007
Phase I/II Study of Concurrent Chemotherapy and Escalating Doses 3-D Conformal Radiotherapy (RT) Followed by Three Cycles of Chemotherapy for Unresectable Non-Small Cell Lung Cancer (NSCLC) Using a New
More informationObjectives Primary Objective: Secondary Objectives For T4 a, b, c tumors:
Z1031 A randomized phase III trial comparing 16 to 18 weeks of neoadjuvant exemestane (25mg daily), letrozole (2.5mg), or anastrozole (1mg) in postmenopausal women with clinical stage II and III estrogen
More informationArm A: Induction Gemcitabine 1000 mg/m 2 IV once a week for 6 weeks.
ECOG-4201 (RTOG Endorsed) ECOG 4201 Pancreas (RTOG Endorsed)-1 Protocol Status: Opened: April 10, 2003 Closed: December 15, 2005 Title: A Randomized Phase III Study of Gemcitabine in Combination with Radiation
More informationJune 2009 Respiratory Committee CALGB 30610
30610 Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide Activated: March 15, 2008 Study Chairpersons: J. Bogart
More informationEORTC (RTOG 0834 Endorsed) Opened: July 22, 2009
January 2011 0834-1 EORTC 26053 22054 (RTOG 0834 Endorsed) Protocol Status: Opened: July 22, 2009 Title: Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic
More information6 cycles* January Opened: January 17, 2006
January 2008 0525-1 RTOG Protocol No: 0525 Protocol Status: Opened: January 17, 2006 Title: Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with
More informationJune Opened: January 17, 2006 Closed: June 13, 2008
June 2009 0525-1 RTOG Protocol No: 0525 Protocol Status: Opened: January 17, 2006 Closed: June 13, 2008 Title: Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide
More informationNCCTG Status Report for Study N April 2008
Phase II Randomized Study of Pemetrexed With Sorafenib Versus Pemetrexed lone as Second-line Therapy in Patients With dvanced Non-Small Cell Lung Cancer Purpose of - Primary Study: 1) To compare the progression-free
More informationNCCTG Status Report for Study N May 2010
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic cid SH), Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Purpose of - Phase I Study: 1) To determine the maximum
More informationGOG PROTOCOL #209 GOG 209
GOG PROTOCOL #209 PROTOCOL Study Chairs Statistician Data Coordinator Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III and
More informationGOG PROTOCOL #209. David Miller, MD, Gini Fleming, MD, Richard Zaino, MD, and David Cella, PhD
GOG PROTOCOL #209 PROTOCOL Study Chairs Statistician Data Coordinator Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III and
More informationFeasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma ABSTRACT Recurrent or progressive pediatric CNS tumors generally have a poor prognosis
More informationChemotherapy plus Radiotherapy versus Radiotherapy Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of RTOG 9402
Chemotherapy plus Radiotherapy versus Radiotherapy Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of RTOG 9402 Gregory Cairncross, Meihua Wang, Edward Shaw, Berndt Scheithauer
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationS0106 Phase III. Coordinating Group: SWOG
S0106 Phase III Coordinating Group: SWOG A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg ) Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationObjectives Primary Objectives:
Z1031 A randomized phase III trial comparing 16 to 18 weeks of neoadjuvant exemestane (25mg daily), letrozole (2.5mg), or anastrozole (1mg) in postmenopausal women with clinical stage II and III estrogen
More informationPhase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas
RTOG 0539 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas Volume 4, Issue 2 September 2012 I N T HIS I SSUE Thoughts From the Chair
More informationProtocol Abstract and Schema
Protocol Abstract and Schema This is a phase I/II study to determine: 1) the maximum tolerated dose (MTD) or recommended phase II dose of ABT-888 in combination with radiation therapy, and 2) the efficacy
More informationEASTERN COOPERATIVE ONCOLOGY GROUP
EASTERN COOPERATIVE ONCOLOGY GROUP E5204 INTERGROUP RANDOMIZED PHASE III STUDY OF POSTOPERATIVE OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN VS OXALIPLATIN, 5-FLUOROURACIL, LEUCOV- ORIN AND BEVACIZUMAB FOR
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationNeuro-Oncology Program
Neuro-Oncology Program The goals of the Neuro-oncology Committee are: 1) to improve duration and quality of life of brain tumor patients; 2) to assess disease and treatment-related effects on neurocognitive
More informationJanuary Opened: April 15, 2009
January 2011 0825-1 RTOG Protocol No: 0825 Protocol Status: Opened: April 15, 2009 Title: Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide
More informationProtocol Abstract and Schema
Protocol Abstract and Schema Phase II study of Bevacizumab plus Irinotecan (Camptosar ) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas,
More informationProtocol Abstract and Schema
Protocol Abstract and Schema A Phase 1 and Phase II Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Description and Rationale: Low grade gliomas are among the most common primary
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationCNAJ12TZRT. Protocol Code. Neuro-Oncology. Tumour Group. Dr. Brian Thiessen. Contact Physician
BC Cancer Protocol Summary for Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Astrocytomas and Oligodendrogliomas with Radiation Protocol Code Tumour Group Contact
More informationHSV1716 Dose levels and Cohort size Dose level No of Patients HSV1716 Dosage 1* 3 to 6 1 ml of 1 x 10 5 infectious units HSV1716 per ml 2
Abstract and Schema: Description and Rationale: Pediatric high grade gliomas have a progressive initial course and high risk of relapse/ progression; making the 5-year overall survival rate 15-35% with
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationAbstract and Schema. Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Abstract and Schema Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Description and Rationale: Low grade gliomas are among the most common primary CNS
More informationBC Cancer Protocol Summary for Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy
BC Cancer Protocol Summary for Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent Adjuvant Temozolomide Radiation Therapy Protocol Code Tumour Group Contact Physician CNELTZRT Neuro-Oncology
More informationThe Clinical Research E-News
Volume 3: ISSUE 3: February 16, 2011 The Clinical Research E-News Now Open: RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis RTOG 1010, A Phase III Trial Evaluating
More informationSUMMARY OF CHANGES Amendment 6, Version Date: March 29, 2010 [Broadcast: April 8, 2010]
Amendment 6, Version Date: March 29, 2010 [Broadcast: April 8, 2010] RTOG 0233, "A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation
More informationNRG ONCOLOGY NRG-CC003
NRG ONCOLOGY NRG-CC003 A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer SCHEMA Histologic proof or unequivocal cytologic
More informationPRESURGICAL PLANNING. Strongly consider neuropsychological evaluation before functional imaging study Strongly consider functional imaging study
NOTE: Consider Clinical Trials as treatment options for eligible patients. Page 1 of 6 RADIOLOGICAL PRESENTATION PRESURGICAL PLANNING TREATMENT Imaging study suggestive of glioma 1 Left hemisphere speech/motor
More information(7) VITAL SIGNS (8) LEVEL OF CONSCIOUSNESS (9) MENTAL STATUS (10) SPEECH (11) VISION (12) FUNDUS (PAPILLEDEMA)
Radiation Therapy Oncology Group Phase II CNS Lymphoma Follow-Up Form RTOG Study No. 1114 Case # Amended Data Yes INSTRUCTIONS: Submit this form as indicated in the protocol. All dates need to be recorded
More informationPlattenepithelkarzinom des Ösophagus, 1 st -line
Plattenepithelkarzinom des Ösophagus, 1 st -line AIO-STO-0309 An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced
More informationJune 2009 Breast Committee CALGB 40502
CALGB 40502/CTSU 40502 A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nabpaclitaxel or ixabepilone combined with bevacizumab as first-line therapy for locally
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationNON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28
More informationAbstract and Schema. Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Abstract and Schema Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Description and Rationale: Low grade gliomas are among the most common primary CNS
More informationProtocol for management of patients with pineal region tumours v1
Protocol for management of patients with pineal region tumours v1 West Midlands Cancer Alliance Coversheet for Cancer Alliance Expert Advisory Group Agreed Documentation This sheet is to accompany all
More informationNCCTG Status Report for Study N May 2010
MARVEL: Marker Validation of Erlotinib in Lung Cancer - A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced
More informationA Phase II Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM)
A Phase II Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM) Morten Mau-Sorensen 1, Scott Plotkin 2, Patrick Wen 3, Andrew
More informationSynopsis. Study Phase and Title: Study Objectives: Overall Study Design
Synopsis Study Phase and Title: Study Objectives: Overall Study Design Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationDr. Sause: Clinical, Research, and Administration. Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah
Dr. Sause: Clinical, Research, and Administration Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah Objectives: Identify Dr. Sause's educational achievements Discuss
More informationRadio-chemo-immunotherapy using the IDO-inhibitor indoximod for children with progressive brain tumors in the phase 1 setting (NCT )
Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for children with progressive brain tumors in the phase 1 setting (NCT02502708) Theodore S. Johnson, M.D., Ph.D. Pediatric Immunotherapy Program
More informationCooperative Group /JCOG. Multi-modality therapy. Cooperative Group. adjuvant therapy. Chemoradiation % % 7.5% 7.2% 7.0% 2.5% 2.1% 19.
2. 1. 3. 4. Cooperative Group 5. /JCOG 1. Multi-modality therapy 2. 3. 4. Cooperative Group 5. adjuvant therapy Chemoradiation 2000 : 239608, 2.5% 2.1% 3.1% 3.2% 4.2% 4.3% 6.4% 6.8% 6.9% 20913 8.7% 8.3%
More informationCécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010
Prophylactic Cranial Irradiation in Lung Cancer Cécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010 Prophylactic cranial irradiation PCI was introduced
More informationThe Clinical Research E-News
Volume 3: ISSUE 11: June 15, 2011 The Clinical Research E-News Reminder: CRA Quarterly Meeting, Philadelphia, PA: 10-11am on Wednesday June 22nd- Virtual Meeting: dial information attached in a separate
More informationSubject ID: I N D # # U A * Consent Date: Day Month Year
IND Study # Eligibility Checklist Pg 1 of 15 Instructions: Check the appropriate box for each Inclusion and Exclusion Criterion below. Each criterion must be marked and all protocol criteria have to be
More informationThe Clinical Research E-News
Volume 3: ISSUE 9: May 18, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: RTOG 0837, A Randomized,
More informationSpecial pediatric considerations are noted when applicable, otherwise adult provisions apply.
DRUG NAME: Lomustine SYNONYM(S): CCNU 1 COMMON TRADE NAME(S): CeeNU CLASSIFICATION: alkylating agent Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM
More information2012 Medicaid and Partnership Chart
2012 Medicaid and Chart or Alabama $525,000.00 $4,800.00 Minimum: 25,000.00 Alaska $525,000.00 Depends on area of state; Minimum: $113,640 $10,000 in Anchorage $1,656 Minimum:$1838.75 Maximum:$2,841 Minimum:
More informationCancer Research Group Version Date: November 5, 2015 NCI Update Date: January 15, Schema. L O Step 1 1,2
Cancer esearch roup ev. 6/14, 2/15, 1/16 Step 2 Schema 5 Arm A: (7 weeks) Step 1 1,2 N Accrual: 515 S Arm S ransoral esection dissections S A N D M Z 4 ntermediate isk 7 Stratify: = 10 pk-yr vs. > 10 pk-yr
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 7: ISSUE 1: January 16, 2015 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationRandomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer This is a two-arm, randomized phase II trial for patients with BRAF mutant
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationNCCTG Status Report for Study N0275 May 2011
NCCTG Status Report for Study N0275 May 2011 Phase II Trial Evaluating Resection Followed by Adjuvant Radiation Therapy (RT) for Patients with Desmoplastic Melanoma Primary Goals 1. Assess the recurrence
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationFinal Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer*
Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer* Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group William
More informationCisplatin Vinorelbine (Oral) therapy +/- radiotherapy
1 REGIMEN TITLE: Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy Page 1 of 5 Indication: First line in Radical/ Induction, Adjuvant and Advanced & Palliative treatment of Non-small cell lung cancer
More informationWelcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar
American College of Surgeons Clinical Research Program Kelly K. Hunt, M.D. Program Director Welcome to American College of Surgeons Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar Moderator:
More informationCOG-ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Page 1 of 6 COG-ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) FAST FACTS Eligibility Reviewed and Verified By
More informationAlliance A Alliance SWOG ECOG/ACRIN - NRG
Preoperative chemotherapy and chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Alliance A021501 Alliance SWOG ECOG/ACRIN - NRG Clinical
More informationChemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer Emily Chan, Qian Shi, Julio Garcia-Aguilar, Peter Cataldo, Jorge
More informationBACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates
2181 Treatment Options for Muscle-invasive Urothelial Cancer for Patients Who Were Not Eligible for Cystectomy or Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Report
More informationBR for previously untreated or relapsed CLL
1 Protocol synopsis Title Rationale Study Objectives Multicentre phase II trial of bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia
More informationCNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
More informationClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: Date: 18 February 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationProtocol Abstract and Schema
Protocol Abstract and Schema A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors Description and
More informationAna Luisa Stuckett, PhD, MS
Ana Luisa Stuckett, PhD, MS alstuckett@mdanderson.org Clinical Studies Coordinator Investigational Cancer Therapeutics (Phase I) MD Anderson Cancer Center Houston, Texas Education Ph.D., Microbiology,
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationIntra-arterial Targeted Delivery of Gemcitabine in Treatment of Patients with Loco-regional Pancreatic Tumors
Intra-arterial Targeted Delivery of Gemcitabine in Treatment of Patients with Loco-regional Pancreatic Tumors Alexander Rosemurgy, M.D., Sharona Ross, M.D., Paul Vitulli, M.D., Florida Hospital Tampa,
More informationClinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS
Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221 Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS 1 Disclosure I have no conflicts of interest to disclose 2 Robotic H&N
More informationSUMMARY OF CHANGES Amendment 5, Version Date: March 24, 2010 Broadcast: 4/6/10
Amendment 5, Version Date: March 24, 2010 Broadcast: 4/6/10 RTOG 0239, "A Phase II Study Of Accelerated High Dose Thoracic Irradiation With Concurrent Chemotherapy For Patients With Limited Small Cell
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationCILENT P Leblond, DIPG Meeting, Barcelone 2012
CILENT-0902 Cilengitide (EMD121974) in combination with irradiation in children and adolescents with newly diagnosed diffuse intrinsic brainstem glioma : Phase I Study P Leblond, DIPG Meeting, Barcelone
More informationIrinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer
Irinotecan Class:Camptothecin Indications : _Cervical cancer _CNS tumor _Esophageal cancer _Ewing s sarcoma _Gastric cancer _Nonsmall cell lung cancer _Pancreatic cancer _Small cell lung cancer _Colorectal
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSelecting the Optimal Treatment for Brain Metastases
Selecting the Optimal Treatment for Brain Metastases Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Understand the benefits, limitations,
More informationAuthor Block M. Fisch, J. W. Lee, J. Manola, L. Wagner, V. Chang, P. Gilman, K. Lear, L. Baez, C. Cleeland University of Texas M.D. Anderson Cancer Ce
Survey of disease and treatment-related t t related symptoms in outpatients with invasive i cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study, Abst # 9619) Michael J. Fisch,
More informationBackground: Brain Mets in Breast Cancer
ANG1005, A Novel Brain-Penetrant Taxane Derivative, for the Treatment of Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer Priya Kumthekar 1, Shou-Ching Tang 2, Andrew Jacob
More informationRadiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
The new england journal of medicine Original Article Radiation plus Procarbazine, CCNU, and Vincristine in Low- Glioma Jan C. Buckner, M.D., Edward G. Shaw, M.D., Stephanie L. Pugh, Ph.D., Arnab Chakravarti,
More informationFAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 5 COG-AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly
More informationRadio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer (NCT )
Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer (NCT02502708) Theodore S. Johnson, M.D., Ph.D. Pediatric Immunotherapy Program Medical College of Georgia (MCG) Georgia
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More informationLONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More information